

A trial to assess whether nivolumab improves survival in relapsed mesothelioma more than placebo

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
27/02/2017	No longer recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input checked="" type="checkbox"/> Statistical analysis plan
02/03/2017	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
18/12/2025	Cancer	

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-nivolumab-for-mesothelioma-confirmed>

Contact information

Type(s)

Public

Contact name

Mrs Kelly Cozens

Contact details

Southampton Clinical Trials Unit
MP131
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Type(s)

Scientific

Contact name

Dr Kayleigh Hill

Contact details

Southampton Clinical Trials Unit
MP131

Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Additional identifiers

Clinical Trials Information System (CTIS)
2016-003111-35

ClinicalTrials.gov (NCT)
NCT03063450

Central Portfolio Management System (CPMS)
32290

Study information

Scientific Title

CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma

Acronym

CONFIRM

Study objectives

The aim of this study is to compare overall survival of nivolumab with placebo in patients with relapsed mesothelioma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

West Midlands - Edgbaston Research Ethics Committee, 06/12/2016, ref: 16/WM/0472

Study design

Randomised; Interventional; Design type: Treatment, Drug, Immunotherapy

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Mesothelioma

Interventions

Patients will be randomised 2:1 to nivolumab or placebo, with twice as many people getting nivolumab as placebo. Randomisation will be stratified by site and epithelioid vs. non-epithelioid.

Active treatment arm: Patients will be treated with nivolumab at a dose of 240mg, every two weeks, infused over 30 minutes until disease progression, to a maximum of 12 months.

Placebo control arm: Patients will receive a placebo consisting of sterile 0.9% sodium chloride, every two weeks, infused over 30 minutes until disease progression, to a maximum of 12 months.

All patients will be followed up for a minimum 6 months and maximum of 5 years.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Nivolumab

Primary outcome(s)

Overall survival will be calculated as time from randomisation until date of death

Key secondary outcome(s)

1. Progression free survival is calculated as time from randomisation to disease progression by RECIST 1.1 or modified RECIST using CT scans at baseline compared to further CT scans after cycles 3 and 6 (each cycle is 14 days)
2. Overall response rate is measured by RECIST 1.1 or modified RECIST using CT scans at baseline compared to further CT scans after cycles 3 and 6 (each cycle is 14 days)
3. Quality of life is measured using EQ-5D-5L at baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation
4. Toxicity is measured using CTCAE V4.03 at baseline, after each treatment cycle (each cycle is 14 days) and each follow up visit
5. Cost effectiveness is measured using a health resource use questionnaire at baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation

Completion date

30/09/2022

Eligibility

Key inclusion criteria

1. Histological confirmation of mesothelioma
2. Prior treatment with at least two lines of platinum based chemotherapy
3. ECOG Performance Status 0-1
4. Evidence of disease progression (which is radiologically assessable through RECIST) on CT scan within 28 days of trial treatment
5. Age 18 and above
6. Screening laboratory values within protocol specified ranges
7. Willing to use adequate contraception methods where applicable

8. Willing to provide blood and tissue samples relating to mesothelioma
9. Expected survival of at least 12 weeks

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

332

Key exclusion criteria

1. Untreated, symptomatic CNS metastases
2. Carcinomatous meningitis
3. Active, known or suspected auto-immune disease
4. Those requiring systemic treatment with corticosteroids or immunosuppressive medications within 14 days of planned first dose
5. Other active malignancy requiring treatment
6. Serious or uncontrolled medical disorder or active infection which would impact on the trial or affect their involvement
7. Prior treatment with anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody
8. History of testing positive for HIV or AIDS or a positive test for Hepatitis indicating acute or chronic infection
9. History of allergy or sensitivity to monoclonal antibodies
10. Women who are pregnant or breastfeeding

Date of first enrolment

27/03/2017

Date of final enrolment

27/03/2020

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Southampton Clinical Trials Unit
MP131
Southampton General Hospital
Tremona Road
Southampton
England
SO16 6YD

Sponsor information

Organisation

University of Southampton

ROR

<https://ror.org/01ryk1543>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available for sharing via controlled access by authorised Southampton CTU (SCTU) staff (as delegated to SCTU by the trial sponsor) and anonymised IPD within the clinical trial dataset will be available for sharing via open access after the trial is published.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		14/10/2021	22/10/2024	Yes	No
Protocol article		18/04/2018	05/10/2022	Yes	No
HRA research summary			28/06/2023	No	No
Plain English results			18/12/2025	No	Yes
Statistical Analysis Plan	version 3	01/08/2022	11/10/2023	No	No